Dermatomyositis is one of the most treatment-resistant inflammatory diseases affecting both skin and muscle, and for decades patients have had few options beyond immunosuppressants with significant toxicity profiles. A prespecified secondary analysis from a large, multinational Phase 3 trial now provides granular evidence that a novel oral dual inhibitor can meaningfully alter cutaneous disease burden — a dimension of dermatomyositis that has historically been underserved by existing therapies.
The VALOR trial enrolled adults with active dermatomyositis across 90 sites in 20 countries between October 2022 and July 2025, randomizing participants to once-daily brepocitinib at 30 mg, 15 mg, or placebo over 52 weeks. This secondary analysis specifically interrogated skin-domain outcomes: changes in the CDASI-A score (a validated measure of cutaneous disease activity), clinically meaningful response thresholds (≥40% relative and ≥4-point absolute improvement), itch severity via Peak Pruritus Numeric Rating Scale, skin-related quality of life via Skindex-16, and binary remission endpoints including a CDASI-A score of 5 or below and investigator-rated clear or near-clear skin status.
Brepocitinib's mechanism — simultaneous inhibition of TYK2 and JAK1 — is pharmacologically relevant to dermatomyositis pathogenesis, which is driven substantially by type I interferon signaling and IL-6/JAK-STAT pathways. This dual blockade distinguishes it from pan-JAK inhibitors and positions it more selectively against the immune axes most implicated in this condition. The 52-week duration is also notable: most earlier dermatomyositis trials were far shorter, making durability data here especially valuable. Key limitations include the trial's excerpt-level reporting available here — effect sizes, response rates by dose arm, and subgroup heterogeneity remain unpublished in full — and the fact that dermatomyositis encompasses both amyopathic and classic subtypes that may respond differently. If the full results confirm statistically robust skin remission rates at the 30 mg dose, this would represent a meaningful step toward disease-modifying therapy for a population with very limited approved options.